Author

Sara R. Savage

Baylor College of MedicineORCID 0000-0002-8170-3132Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Approach:mechanistic / dynamical model· 1 Organism:mouse· 1

Frequent Co-Authors

Bing ZhangiD· 2 shared Alessandro LussanaiD· 1 shared Alex J. SmithiD· 1 shared Alexander B. SaltzmaniD· 1 shared Anna MalovannayaiD· 1 shared Aurélien J. F. DugourdiD· 1 shared Charles M. PerouiD· 1 shared Cheng FaniD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

Bing ZhangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systems BiologyNature CommunicationsPeer-reviewedMay 22, 2025

Comprehensive evaluation of phosphoproteomic-based kinase activity inference

Sophia Müller‐Dott, Eric J. Jaehnig, Khoi Pham Munchic…·Julio Sáez-Rodríguez

This paper evaluates kinase activity inference methods using phosphoproteomics data and benchmarking approaches, finding that curated kinase-substrate libraries significantly impact results.

30 citationstop 2%

proteomicsstatistical model

𝕏 PostBluesky

Cancer BiologyJournal of Clinical InvestigationPeer-reviewedOct 24, 2023

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer

Na Zhao, Elena B. Kabotyanski, Alexander B. Saltzman…·Jeffrey M. Rosen

Zotatifin targets EIF4A to suppress TNBC by inhibiting Sox4, inducing interferon response, and reprogramming the tumor immune microenvironment, synergizing with chemotherapy.

34 citationstop 4%

mousebulk RNA-seq

𝕏 PostBluesky